ATEZOLIZUMAB

atezolizumab 1.2 g/20 mL injection, 20 mL vial

ATEZOLIZUMAB (11807K)

atezolizumab 1.2 g/20 mL injection, 20 mL vial
11807K
Body System:
Manner of administration:Injection
Public
Chemotherapy Items for Public Hospital use
Authority Required (STREAMLINED)

Restriction  18326

Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Initial treatment 1

Restriction  10125

Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Initial treatment 2
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 1200 mg # of repeats: 5 DPMA: $6,838.60 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Tecentriq
(atezolizumab 1.2 g/20 mL injection, 20 mL vial)